Additionally, numerous very well recognized adverse prognostic markers, like U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, lost their damaging effect in clients taken care of with VO. The only real issue that remained predictive of a shorter progression-free of charge survival in this cohort of patients was TP53 aberrations.112 Eventually, the